Clinical trial
A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS…
NCT00411034 · Alza Corporation, DE, USA, Industry · Completed
Key facts
| NCT number | NCT00411034 |
|---|---|
| Title | A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain |
| Official title | A Repeated-Dose Evaluation of Analgesic Use and Safety of Dilaudid SR( Hydromorphone HCI) in Patients With Chronic Cancer Pain |
| Lead sponsor | Alza Corporation, DE, USA, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Analgesics, Opioid, Pain |
| Intervention type | Drug |
| Interventions | OROS Hydromorphone HCI |
| Enrollment | 463 |
| Completion | Sep 1, 1999 |
| First posted | Dec 13, 2006 |
| Last update posted | Apr 27, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: